Document Classification

Section Type: METHODS

Text: This study compared the 24-month efficacy and safety of two immunosuppressive regimens using reduced calcineurin inhibitors (CNIs) exposure with standard dosage of CsA in 240 patients who were randomized into three groups : group A (n = 80) : Thymoglobulin, CsA (4 mg/kg twice daily) plus azathioprine (1. 5 mg/kg once daily) ; group B (n = 80) : basiliximab, CsA (2 mg/kg / twice daily) plus mycophenolate mofetil (MMF ; 1 g twice daily) ; and group C (n = 80) : basiliximab, TAC (0. 05 mg/kg / twice daily) plus MMF (1 g twice daily).